Ipca Labs Licenses BRL's Subcutaneous Biologics Platform

Ipca Laboratories and Bhami’s Research Laboratory (BRL) have entered into a global licensing agreement. This collaboration grants Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform. The agreement focuses on the development and commercialization of multiple monoclonal antibody products targeting oncology and inflammatory diseases. Ipca will handle further research, clinical trials, manufacturing, and launch, while BRL will manage proof-of-concept and formulation development. BRL will receive milestone fees and royalties on net sales upon commercialization. This partnership aims to accelerate the development of affordable biologics for cancer and autoimmune diseases, enhancing patient convenience and safety.